**Core Concept**
The development of hypertriglyceridemia and hypercholesterolemia in a patient being treated for HIV-1 is related to the side effects of certain antiretroviral medications, specifically protease inhibitors. These medications can cause dyslipidemia due to their mechanism of action and the resulting metabolic changes.

**Why the Correct Answer is Right**
Ritonavir is a protease inhibitor used in the treatment of HIV-1. It works by inhibiting the protease enzyme, which is essential for the maturation of viral particles. However, this inhibition also leads to an increase in the levels of triglycerides and cholesterol in the blood, resulting in hypertriglyceridemia and hypercholesterolemia. This is because protease inhibitors can cause insulin resistance, leading to increased glucose and lipid levels in the blood.

**Why Each Wrong Option is Incorrect**
**Option A:** is incorrect. The other options are not protease inhibitors and do not have the same mechanism of action that leads to dyslipidemia. Protease inhibitors like Ritonavir are specifically linked to this side effect.

**Option B:** Raltegravir is an integrase inhibitor, which is a different class of antiretroviral medication. It works by inhibiting the integrase enzyme, which is essential for the integration of viral DNA into the host cell's genome. Integrase inhibitors are not typically associated with dyslipidemia.

**Option C:** Tenofovir is a nucleotide reverse transcriptase inhibitor, which is another class of antiretroviral medication. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of viral RNA into DNA. Nucleotide reverse transcriptase inhibitors are not typically associated with dyslipidemia.

**Option D:** Eirenz (Efavirenz) is a non-nucleoside reverse transcriptase inhibitor, which is a different class of antiretroviral medication. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of viral RNA into DNA. Non-nucleoside reverse transcriptase inhibitors are not typically associated with dyslipidemia.

**Clinical Pearl / High-Yield Fact**
When treating patients with HIV-1, it's essential to monitor their lipid profiles regularly, especially when using protease inhibitors like Ritonavir. This can help identify and manage dyslipidemia early on, reducing the risk of cardiovascular complications.

**✓ Correct Answer: A. Ritonavir, Ritonavir is a protease inhibitor that can cause hypertriglyceridemia and hypercholesterolemia due to its mechanism of action and the resulting metabolic changes.**